Literature DB >> 27232917

Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study.

Claudio Borghi1, Florence Tubach2, Guy De Backer3, Jean Dallongeville4, Eliseo Guallar5, Jesús Medina6, Joep Perk7, Carine Roy8, José R Banegas9, Fernando Rodriguez-Artalejo9, Julian P Halcox10.   

Abstract

BACKGROUND: The prevalence of and factors associated with uncontrolled hypertension and apparent resistant hypertension were assessed in the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; NCT00882336).
METHODS: EURIKA was a cross-sectional observational study including patients being treated for the primary prevention of cardiovascular disease in 12 European countries. Patients were assessed if they were being treated for hypertension (N=5220). Blood pressure control was defined according to European guidelines, with sensitivity analysis taking account of patients' age and diabetes status. Associated factors were assessed using multivariate analysis.
RESULTS: In the primary analysis, a total of 2691 patients (51.6%) had uncontrolled hypertension. Factors significantly associated with an increased risk of having uncontrolled hypertension included female sex (odds ratio [OR]: 2.29; 95% confidence interval [CI]: 1.93-2.73), body mass index (BMI; OR per kg/m(2): 1.03; 95% CI: 1.01-1.04), and geographic location. A total of 749 patients (14.3%) had apparent resistant hypertension. Factors significantly associated with an increased risk of having apparent resistant hypertension included BMI (OR per kg/m(2): 1.06; 95% CI: 1.04-1.08), diabetes (OR: 1.28; 95% CI: 1.06-1.53), use of statins (OR: 1.36; 95% CI: 1.15-1.62), serum uric acid levels (OR: 1.16; 95% CI: 1.09-1.23), and geographic location. Similar results were seen in sensitivity analyses.
CONCLUSIONS: Over 50% of patients treated for hypertension continued to have uncontrolled blood pressure and 14.3% had apparent resistant hypertension. Positive associations were seen with other cardiovascular risk factors.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Hypertension; Observational study; Primary prevention; Risk factor

Mesh:

Year:  2016        PMID: 27232917     DOI: 10.1016/j.ijcard.2016.05.044

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  25 in total

1.  Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up.

Authors:  F Fici; G Seravalle; N Koylan; I Nalbantgil; N Cagla; Y Korkut; F Quarti-Trevano; W Makel; G Grassi
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-05-11

Review 2.  Therapeutic Approach to Hypertension Urgencies and Emergencies During Acute Coronary Syndrome.

Authors:  Giuliano Tocci; Ilaria Figliuzzi; Vivianne Presta; Francesca Miceli; Barbara Citoni; Roberta Coluccia; Maria Beatrice Musumeci; Andrea Ferrucci; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-07-31

3.  Uric Acid Is a Strong Risk Marker for Developing Hypertension From Prehypertension: A 5-Year Japanese Cohort Study.

Authors:  Masanari Kuwabara; Ichiro Hisatome; Koichiro Niwa; Shigeko Hara; Carlos A Roncal-Jimenez; Petter Bjornstad; Takahiko Nakagawa; Ana Andres-Hernando; Yuka Sato; Thomas Jensen; Gabriela Garcia; Bernardo Rodriguez-Iturbe; Minoru Ohno; Miguel A Lanaspa; Richard J Johnson
Journal:  Hypertension       Date:  2017-12-04       Impact factor: 10.190

4.  Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy.

Authors:  Ilaria Figliuzzi; Vivianne Presta; Barbara Citoni; Francesca Miceli; Francesca Simonelli; Allegra Battistoni; Roberta Coluccia; Andrea Ferrucci; Massimo Volpe; Giuliano Tocci
Journal:  Clin Cardiol       Date:  2018-06-05       Impact factor: 2.882

5.  Educational Interventions May Promote Better Blood Pressure Control in Russia.

Authors:  Giuliano Tocci; Ilaria Figliuzzi
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-09-07

6.  European guidelines on lifestyle changes for management of hypertension : Awareness and implementation of recommendations among German and European physicians.

Authors:  J Bolbrinker; L Zaidi Touis; H Gohlke; B Weisser; R Kreutz
Journal:  Herz       Date:  2017-05-22       Impact factor: 1.443

7.  Braylin induces a potent vasorelaxation, involving distinct mechanisms in superior mesenteric and iliac arteries of rats.

Authors:  W A Santos; K M C Dourado; F A Araújo; R L C Jesus; R A Moraes; S C D S Oliveira; Q L Alves; L O Simões; L L Casais-E-Silva; R S Costa; E S Velozo; D F Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-09       Impact factor: 3.000

8.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

9.  Independent predictors of effective blood pressure control in patients with hypertension on drug treatment in Brazil.

Authors:  Francisco Flavio Costa Filho; Ari Timerman; Jose Francisco Kerr Saraiva; Carlos Costa Magalhaes; Ibraim Masciarelli F Pinto; Gustavo B F Oliveira; Antonio Cordeiro Mattos; Alvaro Avezum
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-11-23       Impact factor: 3.738

10.  Baseline and change in serum uric acid predict the progression from prehypertension to hypertension: a prospective cohort study.

Authors:  Xue Tian; Anxin Wang; Yingting Zuo; Shuohua Chen; Dapeng Mo; Licheng Zhang; Shouling Wu; Yanxia Luo
Journal:  J Hum Hypertens       Date:  2021-03-23       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.